Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Down 1.8% – Time to Sell?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares were down 1.8% on Friday . The company traded as low as $677.99 and last traded at $668.25. Approximately 110,467 shares changed hands during mid-day trading, a decline of 82% from the average daily volume of 621,862 shares. The stock had previously closed at $680.61.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on REGN shares. Sanford C. Bernstein cut their target price on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a research report on Tuesday, January 7th. UBS Group downgraded Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price objective for the company from $1,130.00 to $738.00 in a research report on Thursday, January 16th. Leerink Partners upgraded Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and increased their price objective for the company from $762.00 to $834.00 in a research report on Wednesday, February 5th. Bernstein Bank cut their price objective on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. Finally, Robert W. Baird cut their price objective on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating for the company in a research report on Wednesday, February 5th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Price Performance

The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $72.91 billion, a price-to-earnings ratio of 17.42, a P/E/G ratio of 2.34 and a beta of 0.27. The stock’s 50 day moving average price is $694.91 and its two-hundred day moving average price is $833.75.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. The firm had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the business posted $11.86 earnings per share. Analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.53%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is 2.30%.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several hedge funds have recently bought and sold shares of REGN. Capital International Investors boosted its holdings in Regeneron Pharmaceuticals by 41.6% during the fourth quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company’s stock valued at $3,373,859,000 after acquiring an additional 1,390,534 shares during the period. Norges Bank acquired a new position in Regeneron Pharmaceuticals in the fourth quarter worth about $802,036,000. Price T Rowe Associates Inc. MD increased its holdings in shares of Regeneron Pharmaceuticals by 63.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company’s stock worth $1,485,527,000 after buying an additional 810,144 shares in the last quarter. Amundi increased its holdings in shares of Regeneron Pharmaceuticals by 45.8% during the fourth quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company’s stock worth $1,138,074,000 after buying an additional 487,489 shares in the last quarter. Finally, Loomis Sayles & Co. L P increased its holdings in shares of Regeneron Pharmaceuticals by 33.4% during the fourth quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company’s stock worth $1,122,168,000 after buying an additional 393,997 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.